PE20141169A1 - Derivados de etinilo - Google Patents

Derivados de etinilo

Info

Publication number
PE20141169A1
PE20141169A1 PE2013002401A PE2013002401A PE20141169A1 PE 20141169 A1 PE20141169 A1 PE 20141169A1 PE 2013002401 A PE2013002401 A PE 2013002401A PE 2013002401 A PE2013002401 A PE 2013002401A PE 20141169 A1 PE20141169 A1 PE 20141169A1
Authority
PE
Peru
Prior art keywords
pyridin
hydrogen
lower alkyl
ethinyl
ona
Prior art date
Application number
PE2013002401A
Other languages
English (en)
Inventor
Georg Jaeschke
Synese Jolidon
Lothar Lindemann
Heinz Stadler
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20141169A1 publication Critical patent/PE20141169A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P70/00—Climate change mitigation technologies in the production process for final industrial or consumer products
    • Y02P70/50—Manufacturing or production processes characterised by the final manufactured product
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02T—CLIMATE CHANGE MITIGATION TECHNOLOGIES RELATED TO TRANSPORTATION
    • Y02T10/00—Road transport of goods or passengers
    • Y02T10/60—Other road transportation technologies with climate change mitigation effect
    • Y02T10/70—Energy storage systems for electromobility, e.g. batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Secondary Cells (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ETINILO DE LA FORMULA (I), EN LA QUE X ES N, C-R, R ES HIDROGENO, HALOGENO; G ES N, CH; R1 ES FENILO, PIRIDINILO; R2 ES H, ALQUILO INFERIOR, HIDROXI, ENTRE OTROS; R3, R3', R4, R4', R6, R6' CON INDEPENDENCIA ENTRE SI SON HIDROGENO, ALQUILO INFERIOR; R5 ES HIDROGENO, ALQUILO INFERIOR; n ES 0-2; m ES 0-1. SON COMPUESTOS PREFERIDOS (RS)-1,5,5-TRIMETIL-3-(5-(FENILETINIL)PIRIDIN-2-IL)-PIRROLIDIN-2-ONA, (RS)-1,5,5,-TRIMETIL-3-(5-(PIRIDIN-3-ILETINIL)PIRIDIN-2-IL)-PIRROLIDIN-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ES UTIL EN EL TRATAMIENTO DE LA ESQUIZOFRENIA.
PE2013002401A 2011-04-26 2012-04-23 Derivados de etinilo PE20141169A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11163683 2011-04-26

Publications (1)

Publication Number Publication Date
PE20141169A1 true PE20141169A1 (es) 2014-09-22

Family

ID=46025665

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002401A PE20141169A1 (es) 2011-04-26 2012-04-23 Derivados de etinilo

Country Status (33)

Country Link
US (2) US8957213B2 (es)
EP (1) EP2702051B1 (es)
JP (1) JP5753627B2 (es)
KR (1) KR101554803B1 (es)
CN (1) CN103492373B (es)
AR (1) AR086036A1 (es)
AU (1) AU2012247653B2 (es)
BR (1) BR112013026116A2 (es)
CA (1) CA2829170C (es)
CL (1) CL2013003056A1 (es)
CO (1) CO6801734A2 (es)
CR (1) CR20130475A (es)
CY (1) CY1116391T1 (es)
DK (1) DK2702051T3 (es)
EA (1) EA022019B1 (es)
ES (1) ES2534090T3 (es)
HK (1) HK1191330A1 (es)
HR (1) HRP20150555T1 (es)
HU (1) HUE025031T2 (es)
IL (1) IL228835A (es)
MA (1) MA35133B1 (es)
MX (1) MX337443B (es)
MY (1) MY163164A (es)
PE (1) PE20141169A1 (es)
PL (1) PL2702051T3 (es)
PT (1) PT2702051E (es)
RS (1) RS53903B1 (es)
SG (1) SG194120A1 (es)
SI (1) SI2702051T1 (es)
TW (2) TWI436993B (es)
UA (1) UA110378C2 (es)
WO (1) WO2012146551A1 (es)
ZA (1) ZA201306586B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY163164A (en) * 2011-04-26 2017-08-15 Hoffmann La Roche Ethynyl derivatives as positive allosteric modulators of the mglur5
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
LT2875000T (lt) * 2012-07-17 2016-11-10 F.Hoffmann-La Roche Ag Ariletinilo dariniai
MY171517A (en) * 2012-10-18 2019-10-16 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
UA116023C2 (uk) * 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
PL3303316T3 (pl) 2015-06-03 2020-06-29 F. Hoffmann-La Roche Ag Pochodne etynylu
KR20180026438A (ko) 2015-07-15 2018-03-12 에프. 호프만-라 로슈 아게 대사형 글루타메이트 수용체 조절제로서의 에틴일 유도체
US10423423B2 (en) * 2015-09-29 2019-09-24 International Business Machines Corporation Efficiently managing speculative finish tracking and error handling for load instructions
LT3484889T (lt) 2016-07-18 2020-11-10 F. Hoffmann-La Roche Ag Etinilo dariniai
MX2020003821A (es) * 2017-10-10 2023-01-12 Biogen Inc Proceso de elaboración de espiroderivados.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CN101223166B (zh) * 2004-10-07 2011-10-19 默沙东公司 噻唑基mglur5拮抗剂及其应用方法
EP1809620B1 (en) 2004-11-04 2010-12-29 Addex Pharma SA Novel tetrazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
ES2328185T3 (es) 2006-05-31 2009-11-10 F. Hoffmann-La Roche Ag Derivados de aril-4-etinil-isoxazol.
WO2008151184A1 (en) 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
WO2010022125A1 (en) 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
MY163164A (en) * 2011-04-26 2017-08-15 Hoffmann La Roche Ethynyl derivatives as positive allosteric modulators of the mglur5

Also Published As

Publication number Publication date
EP2702051B1 (en) 2015-03-04
ES2534090T3 (es) 2015-04-17
US9212171B2 (en) 2015-12-15
US8957213B2 (en) 2015-02-17
BR112013026116A2 (pt) 2016-12-27
WO2012146551A1 (en) 2012-11-01
CN103492373B (zh) 2015-09-16
EA201391537A1 (ru) 2014-04-30
CO6801734A2 (es) 2013-11-29
EP2702051A1 (en) 2014-03-05
CL2013003056A1 (es) 2014-07-25
RS53903B1 (en) 2015-08-31
JP2014512401A (ja) 2014-05-22
ZA201306586B (en) 2014-05-28
JP5753627B2 (ja) 2015-07-22
US20120277213A1 (en) 2012-11-01
NZ614688A (en) 2015-09-25
DK2702051T3 (en) 2015-03-16
UA110378C2 (en) 2015-12-25
PT2702051E (pt) 2015-05-20
MY163164A (en) 2017-08-15
CA2829170C (en) 2019-02-26
KR20140014256A (ko) 2014-02-05
HUE025031T2 (en) 2016-02-29
CR20130475A (es) 2013-11-11
CA2829170A1 (en) 2012-11-01
EA022019B1 (ru) 2015-10-30
IL228835A0 (en) 2013-12-31
CN103492373A (zh) 2014-01-01
AR086036A1 (es) 2013-11-13
TW201306355A (zh) 2013-02-01
PL2702051T3 (pl) 2015-08-31
TW201311657A (zh) 2013-03-16
CY1116391T1 (el) 2017-02-08
HK1191330A1 (en) 2014-07-25
IL228835A (en) 2016-02-29
HRP20150555T1 (hr) 2015-07-03
TWI436993B (zh) 2014-05-11
AU2012247653A1 (en) 2013-09-26
US20150119384A1 (en) 2015-04-30
MA35133B1 (fr) 2014-05-02
SI2702051T1 (sl) 2015-06-30
MX337443B (es) 2016-03-07
AU2012247653B2 (en) 2016-05-26
MX2013011105A (es) 2013-10-17
SG194120A1 (en) 2013-11-29
KR101554803B1 (ko) 2015-09-21

Similar Documents

Publication Publication Date Title
PE20141169A1 (es) Derivados de etinilo
PE20130155A1 (es) Derivados de ariletinilo
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
PE20091527A1 (es) Derivados de piridazinona
PE20081755A1 (es) Nuevas 2-aminooxazolinas como ligandos taar1
PE20140690A1 (es) Benzoxazepinonas fusionadas como moduladoras de canales ionicos
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
CL2009001044A1 (es) Compuestos cristalinos derivados de heterociclos puenteados por un alqueno; utiles en el tratamiento de enfermedades metabolicas, enfermedades circulatorias, enfermedades del snc, entre otras enfermedades.
PE20140934A1 (es) Derivados de pirazol
PE20151060A1 (es) Nuevos derivados de pirazina como agonistas del receptor cb2
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen
NZ721493A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
MY179862A (en) Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
PE20080207A1 (es) DERIVADOS DE 1-N-AMINO-2-IMIDAZOLIDINONAS COMO INHIBIDORES DEL CANAL DE POTASIO Kv1.5
PE20141168A1 (es) Derivados de pirazolidin-3-ona
PE20090295A1 (es) Derivados de espirociclopropilpiperidina

Legal Events

Date Code Title Description
FG Grant, registration